Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
USD 690 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X4Z2lEPTB;MD6xNwKBkcLz4pEJNE4xOSEQvF2= M2fNXlI2QTZyMkiy
KellyCis83 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMUdihKnDueLCiUCuNFIh|ryP M1fqZlI2QTZyMkiy
SK-N-AS NHH2SppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;WTWM2OD1yLkK05qCKyrIkgJmwMlA{KM7:TR?= MnXqNlU6PjB{OEK=
SK-N-ASCis24 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq1VXNKSzVyPUCuOVfjiIoEsfMAjVAvOTFizszN NVyxSmdtOjV7NkCyPFI>
U87 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnvNE02OCEQvF2= NYDBbWRPPDhiaB?= MWHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KHOrbHnibY5qdg>? M1PUUVI2PzVyMkez
HCT116 NFnObHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLXNE42NTJwNTFOwG0> NIS4cpU1QMLiaNMg MoXaTWM2OD1zLkezxsDDucLiMD6yNeKh|ryP NVzSbmVHOjV5NE[3OlM>
HT-29 NUC2elBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[4NE42NTJwNTFOwG0> MVm0POKhcMLi M3T3NmlEPTB;Nz6yxsDDucLiMT6wOOKh|ryP NGfSfpAzPTd2Nke2Ny=>
Caco2 NH:yOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfOVVY3OC53LUKuOUDPxE1? NFXpPIw1QMLiaNMg M4Xuc2lEPTB;Nz6yOuKhyrIEoEGuOljDqM7:TR?= NWXuRVhPOjV5NE[3OlM>
COLO 205 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWewMlUuOi53IN88US=> M3\lSVQ5yqCqwrC= M{CzSmlEPTB;MT62NeKhyrIEoECuNFLDqM7:TR?= M2DWSVI2PzR4N{[z
SW480 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXewMlUuOi53IN88US=> M2nURVQ5yqCqwrC= Mlu2TWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP NYLqcY1JOjV5NE[3OlM>
HEK293T Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X0N|EuPSEQvF2= NEO5cFE1QMLiaNMg NVHsXlB1UUN3ME2yMlQzyqEEsdMgNE4xPcLizszN NFPBVXkzPTd2Nke2Ny=>
Hep3B  NES0UXNHfW6ldHnvckBCe3OjeR?= MkTTNVAh|ryP M{iwSFQ5yqCqwrC= M{TUVJJm\HWlZYOgeIhmKGWwaHHuZ4lv\yCnZn\lZ5Qhd2ZiQl3QMVY> NHfJWmMzPTZ|M{W2OC=>
Hep3B  M3:x[2Z2dmO2aX;uJGF{e2G7 M1T2TVAvOS1zMDFOwG0> MXqyOEBp MV;zeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? NGjvcIIzPTZ|M{W2OC=>
HEK293 M1n0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHPdIhKSzVyPUeuNVTDqMLzwrCwMlM3yqEQvF2= M4LSXlI2PjB|MUKy
DU145 NXTEXVJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXMTWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP Mn3mNlU3ODNzMkK=
HCT15 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorMTWM2OD1yLkixxsDDucLiMD6wNeKh|ryP MmHHNlU3ODNzMkK=
T47D NUjZRZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\YeWlEPTB;Mz6xPOKhyrIEoECuNVHDqM7:TR?= MlPwNlU3ODNzMkK=
SMMC-7721 NEHNbYRHfW6ldHnvckBCe3OjeR?= NYPnTZU4PDBizszN Ml\EOFghcA>? NUTlN49sTE2VTx?= NF7jZmtqdmS3Y3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdg>? NHGwe|kzPTV2NEO2NS=>
MDA-MB-231 M3PYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnpbGI4OsLiaB?= NWX4eI9nUUN3ME2yNU4zyqEEsdMgOE4zyqEQvF2= NFLrU4UzPTR6NkKxPS=>
MCF-7 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrxTYI4OsLiaB?= MmLFTWM2OD1zMD65xsDDucLiMj6xxsDPxE1? NIP2bpczPTR6NkKxPS=>
Jurkat M{TIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3ObVRKPzMEoHi= NHHlPGJKSzVyPUGuNuKhyrIEoEGuOeKh|ryP MmfzNlU1QDZ{MUm=
HeLa NFfGd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfvNlM5PzMEoHi= NH;kXXpKSzVyPUOuPeKhyrIEoEKuN:Kh|ryP M2PQZ|I2PDh4MkG5
MCF7  M3f0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnjO4s3PS1zMECg{txO NGfNeYk4KGR? Mor0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFPzRYgzPTR5Mk[xPS=>
K562 NYWx[lY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\DdlczyqCq MX3JR|UxRTBwMkpCpO69VQ>? NFX2Ro8zPTJ6Mk[1Ny=>
K/VP.5 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LsUlczyqCq M33NVmlEPTB;ND65xsDPxE1? Mn\kNlUzQDJ4NUO=
SH-EP  M4C4d2Z2dmO2aX;uJGF{e2G7 NGDaR4ozOMLizsznM41t NYPEbGFEOjUEoHi= NV;hVXhncW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGWwZH;n[Y5wfXNiRFXQVC=> M1LtWVI2OjZzOUix
SCC25 M2XS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPiNlTDqGh? M2CxZWlEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= M3LxfVI2OjJyN{K5
CAL27 NFHuO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXeyOOKhcA>? M3zMSGlEPTB;NUKuNeKhyrIEoEGuNFnDqM7:TR?= MWOyOVIzODd{OR?=
FaDu MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrUXXgzPMLiaB?= M4DN[WlEPTB;MkWuPFnDqMLzwrCxMlE{yqEQvF2= NIDrNnYzPTJ{MEeyPS=>
SCC25 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzWelc1QMLiaB?= NHH1S3NKSzVyPUKwMlg3yqEEsdMgNU4xP8LizszN MYiyOVIzODd{OR?=
CAL27 M4f5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\MNFQ5yqCq Mk\NTWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= NVjVOnlTOjV{MkC3Nlk>
FaDu M{K4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;0OFjDqGh? MUPJR|UxRTZwNERCpOKyyqBzLkGzxsDPxE1? MXWyOVIzODd{OR?=
SCC25 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;GOVVUPzMEoHi= M3jX[GlEPTB;OD60NeKhyrIEoEGuNVHDqM7:TR?= NYnPXmM4OjV{MkC3Nlk>
CAL27 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYm3NuKhcA>? NGf2WI1KSzVyPUSuNlfDqMLzwrCxMlE1yqEQvF2= MYmyOVIzODd{OR?=
FaDu Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nsclczyqCq NIPlZZNKSzVyPUWuNFLDqMLzwrCxMlE2yqEQvF2= MkHxNlUzOjB5Mkm=
MCF-7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETRV|c1QMLiaNMg MWTEUXNQ M4fyR2lEPTB;Nz6yxsDDucLiMD64xsDPxE1? NHXiOVgzPTJzNkO3PC=>
T-47D NW\XOHFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3rcXY1QMLiaNMg MWnEUXNQ NV30WFAyUUN3ME23MlfDqMLzwrCwMlfDqM7:TR?= NH[xPVUzPTJzNkO3PC=>
MDA-MB-231 NXK2UYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr2cGs4PDkEoHlCpC=> M1jxV2ROW09? MnXjTWM2OD1zMj64xsDDucLiMT6wxsDPxE1? NYXJN5p{OjV{MU[zO|g>
DU145 NUDYbGM1SXCxcITvd4l{KEG|c3H5 MmTTNVAuOTByIN88US=> Mk\6PEBp MYjEUXNQ MlfLbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w MX6yOVE1QTZ6MR?=
DU145 stem-like M2WxU2Fxd3C2b4Ppd{BCe3OjeR?= MXyxNE0yODBizszN MVy4JIg> MVvEUXNQ M4DGTolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGHF[4kzPTF2OU[4NS=>
DU145 MX;GeY5kfGmxbjDBd5NigQ>? MYSxNE0yODBizszN M1W3S|IhcA>? M4PKOGROW09? NUH4WItjcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYCyOVE1QTZ6MR?=
DU145 stem-like NISyc25HfW6ldHnvckBCe3OjeR?= NFLpUmkyOC1zMECg{txO MYWyJIg> NFn5SnFFVVOR MWnpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVOyOVE1QTZ6MR?=
UW228-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfyNE4xOS1|MECg{txO MV20PEBp NUjNRnFQTE2VTx?= NV7a[m1CUUN3ME2wMlk6yqEQvF2= NUDGWlFzOjVzMUmxPFU>
NSCs NVTrVXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zMTVAvODFvM{CwJO69VQ>? MVK0PEBp M2jEbmROW09? MWXJR|UxRTBwMz2zxsDPxE1? MXyyOVEyQTF6NR?=
MKL-1  NE\nd|VHfW6ldHnvckBCe3OjeR?= MWSxNE0yODByIH7N NFXPRlQ1KGR? MVTpcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? NIrEZZAzPTFzNke1OC=>
MCF7 EV MXjGeY5kfGmxbjDBd5NigQ>? MXGxNE0yODBizszN NV\BXFJqOuLCiXi= NUHXfZZNcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? MnraNlUxQDh{MEO=
MCF 7BMI1 NH\ZTmpHfW6ldHnvckBCe3OjeR?= MXqxNE0yODBizszN MoC2NwKBkWh? NU\MepNGcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? MorkNlUxQDh{MEO=
MCF7 EV MYnGeY5kfGmxbjDBd5NigQ>? M3fHSFExNTFyMDFOwG0> M3K4UVLjiImq NEX2UFhGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> MWOyOVA5QDJyMx?=
MCF7 BMI1 MnnISpVv[3Srb36gRZN{[Xl? NFviRnAyOC1zMECg{txO M{Ttd|LjiImq NEWwXmlGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> MmDwNlUxQDh{MEO=
HepG2 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK2c|NFVVORwrC= NIe0WIRKSzVyPUOwMlE3yqEEsdMgNE42OMLizszN Mmr6NlUxPzh|MUG=
MOLT-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX0eY1FVVORwrC= M13QdmlEPTB;MD6wOVHDqMLzwrCwMlAxOsLizszN MYSyOVA4QDNzMR?=
HT1080 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInBOHEyNTFyMDFOwG0> NVv6XoN3PC9{ND:0PEBp M4jo[2ROW00EoB?= NV;NWFN4cW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u Mn3aNlUxPzhyNkS=
HT1080 NUC1dJdiTnWwY4Tpc44hSXO|YYm= MXWwMlAxODFvMUCwJO69VQ>? NFH6RXoyNTJ2IHi= M2nyOWROW00EoB?= MYrpcoR2[2W|IICtdFU{MHOnckG1LUBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? M4joZlI2ODd6ME[0
HT1080 NF\xbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e3R|AvODByMT2xNFAh|ryP NGfrOGMzPCCq MWXEUXNQyqB? M1zTToNifXOnczDhckBqdmO{ZXHz[UBqdiC2aHWgcpVu[mW{IH;mJINmdGy|IHnuJGczN01uIIfobYxmKGSnY4LlZZNqdmdiUzDhcoQhTzFicHjhd4Uh[2WubIO= MU[yOVA4QDB4NB?=
HD-MY-Z MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M364[VI1NzR6L{eyJIg> MlLFTWM2OO,:nkGwNEDPxE1? NUfvWFU6OjVyNEiyN|Y>
DOHH-2 NIqxR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jOUVI1KGh? NHLNbWhKSzVy78{eNVAxKM7:TR?= NYTUXm15OjVyNEiyN|Y>
DOHH-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWW0PEBp MYfJR|UxRTF7LkpCpO69VQ>? M1nu[VI2ODR6MkO2
DOHH-2 NFP2NphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3ES2lEPzJiaB?= MVzJR|UxRTYEoN88US=> NGLXdlMzPTB2OEKzOi=>
REH MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTJNlQhcA>? NVXFdoVZUUN3ME2wMlAzP8LizszN NVjGV49wOjVyNEiyN|Y>
REH MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVG0PEBp MU\JR|UxRTBwMEG0xsDPxE1? MkfiNlUxPDh{M{[=
REH NHXBb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zQW|czKGh? M33lV2lEPTB;MD6wNVXDqM7:TR?= NYHqbY91OjVyNEiyN|Y>
HH NGDhT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;HNlQhcA>? MlzwTWM2OD1zMESuO:Kh|ryP MonLNlUxPDh{M{[=
HH MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDXNIc1QCCq NXy1UolFUUN3ME20PE43yqEQvF2= MkXHNlUxPDh{M{[=
HH NHL4RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37NPVczKGh? NWP0S3ZoUUN3ME2xOE44yqEQvF2= M2XMPFI2ODR6MkO2
HuT-78 NWHYN5lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn4NlQhcA>? MWLJR|UxRTlwM9Mg{txO NXHzPYl5OjVyNEiyN|Y>
HuT-78 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTiOFghcA>? NFnufWtKSzVyPUSuN:Kh|ryP NYXabplEOjVyNEiyN|Y>
HuT-78 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\xe404OiCq NXLR[IR4UUN3ME20MlLDqM7:TR?= NWTtbYlTOjVyNEiyN|Y>
OPM-2 NYfNeJVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTsW2c6OjRiaB?= NFzGVHBKSzVyPUK0MlHDqM7:TR?= MljTNlUxPDh{M{[=
OPM-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DoXVQ5KGh? MnTJTWM2OD12wrFOwG0> NFXjRWQzPTB2OEKzOi=>
OPM-2 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vsRVczKGh? M4jpO2lEPTB;MT6zxsDPxE1? M3HCSFI2ODR6MkO2
RPMI-8226 M4r3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fPXFI1KGh? Mmf1TWM2OD1zME[uOuKh|ryP MknnNlUxPDh{M{[=
RPMI-8226 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17YZVQ5KGh? MleyTWM2OD17MT6xxsDPxE1? M4XvSlI2ODR6MkO2
RPMI-8226 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm3NkBp MVfJR|UxRTF2LkpCpO69VQ>? MnrZNlUxPDh{M{[=
U-266 NUP0PW1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDTNlQhcA>? MojSTWM2OD16Nj6yxsDPxE1? NHHZSoIzPTB2OEKzOi=>
U-266 M3\UcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\mfZA1QCCq MYDJR|UxRTZ6LkVCpO69VQ>? NFL0eFUzPTB2OEKzOi=>
U-266 NIi0eG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS3NkBp NULvdXM1UUN3ME2yO{41yqEQvF2= Ml\BNlUxPDh{M{[=
Kelly NIjhc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[5SlMxNTFyIN88US=> MkDnO|LDqGh? M4TZXmlEPTB;MT61NVjDqM7:TR?= MVWyOVAxQDlyMB?=
SH-SY5Y  MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTnW4wxNTFyIN88US=> MnPMO|LDqGh? NEjZXZVKSzVyPUCuO|U1yqEQvF5CpC=> MYWyOVAxQDlyMB?=
SK-N-AS NXjZTWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXjd2ZZOC1zMDFOwG0> Mmn1O|LDqGh? NXP0NpZ{UUN3ME2xMlcyOsLizszNxsA> M3\kZlI2ODB6OUCw
SK-N-DZ M1Llb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnKfIoxNTFyIN88US=> NWnHOllYPzMEoHi= NYHFNml2UUN3ME21MlQ5PcLizszN Mk[zNlUxODh7MEC=
HepG2 NHjPVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDyOFjDqGh? MV;EUXNQyqB? NGW5WmJKSzVyPUGzMlY2yqEEsdMgNE46OsLizszN MX2yOFk6PjF|Nh?=
A549 NW\ST4JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK0POKhcA>? NYfxSJhoTE2VT9Mg MUPJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= NV;Ie|hnOjR7OU[xN|Y>
MCF7 NV;5U5NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq0POKhcA>? NWmzT|JOTE2VT9Mg M{PsTGlEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN MlvkNlQ6QTZzM{[=
HL-60  M4LmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;yO|LDqGh? M2\UfmlEPTB;MD6xNwKBjc7:TR?= NVv1eYxnOjR7OUOwNVQ>
HL-60[R] M3XRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;HTWs4OsLiaB?= Mk\nTWM2OD1|LkGy5qCG|ryP MYqyOFk6OzBzNB?=
MIAPACA NU\3WoRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjjS2k2OD1zLkOgxtEhOC5yMzFOwG0> MX:yOFk2Ozh{MR?=
MCF-7 NIjK[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPHTVUxRTBwMkWgxtEhOC5zIN88US=> MlXQNlQ6PTN6MkG=
HeLa MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITC[2RIUTVyPUCuOlQhyrFiMD60JO69VQ>? NFjhe3YzPDl3M{iyNS=>
MO59K  NXjaZ|ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[3JIQ> NILTblRKSzVyPUCuNVfjiIYQvF2= M4OxUFI1QTV|NU[x
MO59J MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jIXVch\A>? M{n6ZWlEPTB;MD6x5qCG|ryP MmriNlQ6PTN3NkG=
ME 180 M2f1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrOdXE1QMLiaNMg NXOxNoZHUUN3ME24MlnDqMLzwrCwMlPjiIYQvF2= NYfrRVBuOjR7NUOwNlc>
MCF-7 MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvwRWI1QMLiaNMg M{jsc2lEPTB;MkOuPUDDuSByLkRihKXPxE1? MWmyOFk2OzB{Nx?=
HeLa MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHVXoZCPDkEoHlCpC=> MmGyTWM2OD12LkexJOKyKDFwNPMAie69VQ>? M17tb|I1QTV|MEK3
MDA-MB-453 M3X2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDmPYh2PDkEoHlCpC=> M325[WlEPTB;MUKuOUDDuSByLki15qCG|ryP M1\Y[|I1QTV|MEK3
MDA-MB-231 NEjJ[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLPUoRjPDkEoHlCpC=> MlvDTWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP NHPJTXAzPDl3M{CyOy=>
PC-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm0POKhcMLi NIDvTXpKSzVyPUG0MlQhyrFiMz6yN-KBjc7:TR?= MWeyOFk2OzB{Nx?=
HT-29 MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPUOFjDqGkEoB?= M{HvTWlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= NFX5PVYzPDl3M{CyOy=>
BGC-823 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUe0POKhcMLi MVvJR|UxRTR|Lke0JOKyKDVwMURihKXPxE1? NVHkPXA1OjR5OUO4O|c>
HeLa NVSwUVBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVW0POKhcMLi NFLFOZdKSzVyPUKwPU46OCEEsTCxN{41OiEkgJZOwG0> MYmyOFc6Ozh5Nx?=
A549 NEnXRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O2NlQ5yqCqwrC= MVLJR|UxRTF|OT61OEDDuSB5LkC15qCG|ryP NHrw[VkzPDd7M{i3Oy=>
HK-2 NUS2WY1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDJVXkyPDkEoHlCpC=> NX6ybmNzUUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= MXuyOFc6Ozh5Nx?=

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+30% PEG 300+H2O
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID